Biontech Se

This study tests an updated COVID-19 vaccine designed for the 2025-2026 season. It includes 760 people aged 12 and older who are at higher risk of severe COVID-19, such as those with underlying health conditions or aged 65+. Participants receive one shot, and researchers monitor …

This study tests two experimental vaccines designed to prevent tuberculosis (TB) in adults who have already received the BCG vaccine and are HIV-negative. About 500 healthy volunteers aged 18 to 55 (or older) will receive different doses to find the safest and most effective dose…

This study tests whether an updated COVID-19 vaccine can safely protect healthy adults aged 50 to 64 from the virus. About 5,240 participants will receive either the variant-adapted vaccine or a placebo. Researchers will monitor side effects and track how many people get COVID-19…

This early-stage trial tests a new vaccine designed to prevent genital herpes caused by HSV-2 (and possibly HSV-1). About 318 healthy adults aged 18-55 will receive different doses to check safety and immune response. The goal is to see if the vaccine is safe and triggers the bod…

This study tests an updated COVID-19 vaccine in healthy children aged 6 months to 12 years. The goal is to see if the vaccine is safe and triggers a strong immune response. Children who have or haven't had a COVID-19 vaccine before can join. The study will track side effects and …

This study tests an updated COVID-19 vaccine (2025/2026 formula) in 343 children aged 5 to 11 who have health conditions that make them more likely to get very sick from COVID-19. Each child gets one shot in the arm and is followed for about 6 months. The goal is to see if the va…

This phase 2 trial tests an experimental mRNA vaccine (RO7198457) in 327 people with stage II or III colorectal cancer who had surgery but still have cancer DNA in their blood. The vaccine is designed to train the immune system to attack remaining cancer cells. Participants are r…

This early study tests whether the experimental drug BNT314 is safe when given alone to people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive increasing doses to find the highest dose with manageable side effects. The go…

This study tests a new drug called BNT327 combined with chemotherapy in people with a hard-to-treat type of lung cancer (small-cell lung cancer). About 110 adults will take part, some getting the combo as their first treatment and others after earlier treatments stopped working. …

This study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer. The goal is to see if the combination can shrink tumors and control the disease. About 83 adults will take part, and researchers will monitor side effects a…